Metro Mining Limited (MMI) Q3 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

across core markets to achieve break even for the whole company. So let me break down the strong top line numbers from the quarter. We delivered a record quarter for our core tests, up 88% year on year with continued growth and clinical adoption in both Australia and the United Kingdom. So in Australia, we saw Meta Explore achieve record sales for the quarter, continued growth in ordering clinicians, And we released landmark meta explore study results from over 4,600 patients identifying actionable results in over 70% of cases. And we released breakthrough study results for meta panel showing the ability to detect undiagnosed pathogens in 20% of patients with 80% of those not routinely detected with any standard testing. In the UK, Full market access for MetaExplorer was achieved to target at the end of May, with June then delivering a record month. And that delivered a record strong growth result for the quarter, with the product now representing 66% of all GI tests sold in the UK when we got to the end of June as we complete the transition and discontinuation of legacy product lines. And useful to call out on this chart related to our guidance and break even objectives for FY26, we expect a similar growth profile in FY26 as we had in FY25. So remaining consistent in Q1 and then stepping up each quarter aligned to growth in clinician adoption and usage in conjunction with planned product feature releases. In the prior quarter, so Q3, to support all investors to understand our transition of product and revenue mix, we put out guidance for Q4 and for the full financial year. So I was very pleased when we released the results to state that we delivered in line with our guidance, landing in the middle of the range with a full FY25 revenue result of 15.67 million, which ...